Narrow search
Showing 1 - 10 of 36,601
Cover Image
Incremental Cost-Effectiveness Analysis of Intravenous Ganciclovir Versus Oral Ganciclovir in the Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis in Patients wit...
Rachlis, Anita; Smaill, Fiona; Walker, Valery; … - In: PharmacoEconomics 16 (1999) 1, pp. 71-84
, intravenous (IV) ganciclovir, in the maintenance treatment of newly diagnosed cytomegalovirus (CMV) retinitis in patients with … and family physicians estimated the following in relation to IV ganciclovir treatment for CMV retinitis and related … whose CMV retinitis stabilised were randomised to maintenance therapy with either IV ganciclovir (5 mg/kg/day; n = 57) or …
Persistent link: https://www.econbiz.de/10005404773
Cover Image
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS: An Overview and Methodological Discussion
Freedberg, Kenneth A.; Paltiel, A. David - In: PharmacoEconomics 14 (1998) 2, pp. 165-174
Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an...
Persistent link: https://www.econbiz.de/10005449227
Cover Image
Economic Evaluation of Systemic Treatments for Cytomegalovirus Retinitis in Patients with AIDS
Lee, Todd A.; Sullivan, Sean D.; Veenstra, David L.; … - In: PharmacoEconomics 19 (2001) 5, pp. 535-550
induction and maintenance (cidofovir IV/IV); 2. IV foscarnet induction and maintenance (foscarnet IV/IV); 3. IV ganciclovir …Objective: To determine the cost of using systemic therapy to treat newly diagnosed cytomegalovirus (CMV) retinitis in …: Swiss healthcare system. Patients and participants: Patients with AIDS and newly diagnosed CMV retinitis. Interventions …
Persistent link: https://www.econbiz.de/10005243151
Cover Image
Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox Presented in part at the Society of General Internal Medicine 16th Annual Meeting: 1993 Apr; Washingto...
Smith, Kenneth J.; Roberts, Mark S. - In: PharmacoEconomics 13 (1998) 5, pp. 645-651
Treatment of adult chickenpox with aciclovir is controversial because of the relatively high cost of medication and small proven benefits of therapy. A decision-tree model was used to estimate the cost effectiveness of aciclovir, from third-party payer and societal perspectives: the incremental...
Persistent link: https://www.econbiz.de/10005243155
Cover Image
The Dilemma of New Drugs: Are Costs Rising Faster than Effectiveness?
Mason, James; Freemantle, Nick - In: PharmacoEconomics 13 (1998) 6, pp. 653-657
This century has seen a phenomenal growth in the development, understanding and use of pharmaceuticals. Additionally, this period has seen the balance of the treatment needs of patients shift dramatically from infectious to cardiovascular and cancer diseases, and from infancy and middle-age to...
Persistent link: https://www.econbiz.de/10004990339
Cover Image
Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis
Rosner, Andrew J.; Grima, Daniel T.; Torrance, George W.; … - In: PharmacoEconomics 14 (1998) 5, pp. 559-573
Objective: The aim of this study was to evaluate the cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Design: A retrospective, incremental cost-effectiveness analysis was conducted from a societal...
Persistent link: https://www.econbiz.de/10005449086
Cover Image
Cost Effectiveness of Pramipexole in Parkinson's Disease in the US
Hoerger, Thomas J.; Bala, Mohan V.; Rowland, Clayton; … - In: PharmacoEconomics 14 (1998) 5, pp. 541-557
Objective: Pramipexole was recently approved in the US for treatment of the symptoms of idiopathic Parkinson's disease (PD). Although pramipexole has been found to be safe and efficacious when compared with placebo, little data are yet available on its cost effectiveness when compared with...
Persistent link: https://www.econbiz.de/10005449262
Cover Image
Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
Brown, Adalsteinn D.; Garber, Alan M. - In: PharmacoEconomics 14 (1998) 1, pp. 27-48
Although risk-factor modification has gained wide acceptance as an effective approach to the prevention of coronary heart disease (CHD), health planners, physicians and patients confront considerable uncertainty over the most appropriate and efficient preventive strategies. Some preventive...
Persistent link: https://www.econbiz.de/10005404785
Cover Image
Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS
Ackerman, Stacey J.; Sullivan, Erin M.; Beusterien, … - In: PharmacoEconomics 15 (1999) 2, pp. 179-195
Objective: Amyotrophic lateral sclerosis (ALS) is a fatal, degenerative neuromuscular disease characterised by a progressive loss of voluntary motor activity. Recombinant human insulin-like growth factor I (rhIGF-I) has been shown to be useful in treating ALS. The purpose of this study was to...
Persistent link: https://www.econbiz.de/10005404963
Cover Image
Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year
Torrance, George; Walker, Valery; Grossman, Ronald; … - In: PharmacoEconomics 16 (1999) 5, pp. 499-520
Objective: To undertake a 1-year prospective economic evaluation of ciprofloxacin compared with usual antibacterial care (any antibacterial other than a quinolone) for the treatment of acute exacerbations of chronic bronchitis (AECB) in adults presenting with a type I or type II AECB. Design:...
Persistent link: https://www.econbiz.de/10005404991